
Personalized treatment for HER2+ breast cancer is achievable through a novel molecular classifier test.


coremsg

The multiparameter molecular classifier test has a high negative predictive value (NPV), underscoring its accuracy for identifying patients who may not be good candidates for treatment de-escalation.

New Test for HER2+ Breast Cancer to Personalize Therapy

new-test-for-her2-breast-cancer-to-personalize-therapy


New Test for HER2+ Breast Cancer to Personalize Therapy
